摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

sery106 | 1204141-31-0

中文名称
——
中文别名
——
英文名称
sery106
英文别名
4-(5-phenyl-1H-pyrazol-3-yl)benzene-1,2-diol
sery106化学式
CAS
1204141-31-0
化学式
C15H12N2O2
mdl
——
分子量
252.272
InChiKey
OLGSNGIIDJSABR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    69.1
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    一种结合 3,5-二取代吡唑的短疏水肽​​作为具有 DNA 促旋酶抑制作用的抗菌剂
    摘要:
    大多数活生物体中都含有抗菌肽 (AMP)。它们的作用方式是独特的,不同于传统的抗生素。尽管已经研究了几类抗菌肽,但它们对微生物的作用机制尚不清楚,否则将为进一步开发新的药物化合物提供坚实的背景。目前的工作描述了肽-吡唑缀合物的抗菌活性的合成和评价。评估了这些缀合物针对革兰氏阳性和革兰氏阴性细菌菌株的抗菌效力,发现与单独的肽和简单的吡唑化合物相比,肽-吡唑缀合物的抗菌效力增强。分子对接研究表明,配体PH3、PH4、PH10对关键蛋白质非常有效。化合物PH3、PH4和PH10在 DNA 促旋酶的假定结合位点附近结合,对接得分为 -6.54、-8.2 和 -7.09 kcal/mol。
    DOI:
    10.1016/j.molstruc.2022.134661
点击查看最新优质反应信息

文献信息

  • NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    申请人:Giese Armin
    公开号:US20110293520A1
    公开(公告)日:2011-12-01
    The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R 1 )(R 2 )—, —C(R 3 )═, —N(R 4 )—, —N═, —N + (R 5 )═, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).
    本发明涉及一种由公式(E)表示的化合物。本发明还涉及一种由公式(E)表示的化合物,用于治疗或预防与蛋白质聚集和/或神经退行性疾病相关的疾病。此外,本发明涉及包含本发明化合物的制药和诊断组合物,以及一种试剂盒。此外,本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备可检测标记的本发明化合物的试剂盒。公式(E)中,X、Y和L分别独立地从—C(R1)(R2)—、—C(R3)═、—N(R4)—、—N═、—N+(R5)═、—O—和—S—中非定向选择;M和Z分别独立地从公式(I)和公式(II)中非定向选择。
  • Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases
    申请人:Ludwig-Maximilians-Universität München
    公开号:EP2687513A1
    公开(公告)日:2014-01-22
    The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    本发明涉及一种由式(E)代表的化合物。本发明还涉及一种由式(E)代表的化合物,用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外,本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外,本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
  • Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
    申请人:LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN
    公开号:US10435373B2
    公开(公告)日:2019-10-08
    The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    本发明涉及一种由式(E)代表的化合物。本发明还涉及一种由式(E)代表的化合物,用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外,本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外,本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
  • NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    申请人:Ludwig-Maximilians-Universität München
    公开号:EP2307381B1
    公开(公告)日:2021-01-13
  • DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    申请人:Ludwig-Maximilians-Universität München
    公开号:EP2687513B1
    公开(公告)日:2020-12-02
查看更多